Navam Capital, a Kolkata based early stage venture capital firm, has put $1 million as seed capital into Vyome Biosciences Pvt Ltd, a new venture focused on dermatology and skin care. Vyome will be developing novel, research-based pharmaceutical solutions for anti- fungal indications, chronic wound healing and for pigmentary disorders of the skin such as vitiligo, according to a release.
The company was founded by Dr Shiladitya Sengupta of Harvard Medical School and Dr Rajesh Gokhale of Institute of Genomics and Integrative Biology in August 2010. The duo have published over 75 peer-reviewed scientific papers between them.
Rajeev Mantri, Executive Director of Navam Capital, said, “Vyome is entering a large market with a strong technical differentiation. Vyome will become a disruptive innovator in this space by combining scientific excellence with innovative management and a keen eye on the market and consumer needs.”
The global dermatology and wound care market is estimated at over $15 billion.
Navam Capital is the early-stage investment arm of Kolkata based GPSK Investment, and focuses on early stage investments on advanced materials, life sciences, clean technology, Internet and other emerging technologies. The investment firms identifies, licenses, develops and commercializes technology, moving it from the laboratory to the market.